Additional file 1: of Evaluating long-term effectiveness of sleeping sickness control measures in Guinea

Model Equations. (PDF 73 kb

miRNAs with altered abundance in sleeping sickness.

<p>Data for the miRNAs from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0067312#pone-0067312-t001" target="_blank">Table 1</a> are illustrated, showing the Log2 fold changes for individual patients. The color code for the spots is at top right.</p

Sample classification based on multiple diagnostic tests.

<p>The patient codes are shown on the left. Mn-BC: Buffy coat mini concentration column, number of parasites; “+” means present but not counted; Cell: white cell count in CSF for staging; PCR: presence of parasite DNA; Trypanolysis: positive result from the trypanolysis test; Status: Ser+ − positive by CATT; AT: previously treated patient. miR expression pattern: A = more similar to infected, B = more similar to control.</p

Cluster dendrogram for all samples.

<p>The samples were classified according to miRNA expression patterns, using the miRNAs in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0067312#pone-0067312-t001" target="_blank">Table 1</a>, and a dendrogram was made to show the relationships. The color codes are shown on the Figure.</p

miRNAs with altered abundance in sleeping sickness.

<p>All miRNAs that showed some alteration in at least one stage of sleeping sickness are shown. Log2 FC is Log2 of the arithmetic mean fold change in patients relative to the average value for controls. The p-values are also shown. Student’s t-tests were used to compare paired and multiple groups, with a Benjamini-Hochberg correction for false discovery. A threshold of 0.05 was set for significance. Although some miRNAs were significantly altered in only one stage, further analysis of these showed no significant difference between stage I and stage II.</p

Cytokine profiles and infection outcomes in gambiense HAT.

<p>Cytokine profiles and infection outcomes in gambiense HAT.</p

Ebola virus disease and HAT treatment centers spatial distribution.

<p>This figure shows the spatial distribution of Ebola virus disease (EVD) incidence with both EVD and Human African Trypanosomiasis (HAT) treatment centers and newly diagnosed HAT cases during the study period (before and during Ebola outbreak) in coastal Guinea. *HAT: Human African Trypanosomiasis. ¥ Before Ebola: from Feb.2012 to Dec.2013. § During Ebola: from Jan.2014 to Oct.2015.</p

Impact of Ebola outbreak on HAT testing and caring activities in Guinea, January 2012 to October 2015.

<p>This panel figure displays: (A) Monthly evolution of the number of persons diagnosed during active campaigns by HAT treatment center; (B) Monthly evolution of the number of persons tested passively by HAT treatment center (and as from 2014 corresponding district); (C) Monthly evolution of the number of persons initiating therapy by HAT treatment center; (D) Monthly evolution of the number of persons initiating HAT therapy according to the type of screening; (E) Monthly evolution of the number of persons initiating HAT therapy by disease stage at diagnosis (F) Monthly evolution of the number of persons attending 3 months post-treatment follow-up visit. HAT: Human African Trypanosomiasis: *Passive routine testing data were available only between January 2014 and October 2015. **All post-treatment follow-up visits were centralized at the Dubreka center whatever the place where the patients received HAT therapy (Dubreka, Boffa or Forecariah HAT centers).</p

Timeline of the Ebola epidemic and HAT control activities.

<p>This figure shows in parallel the main events of the Ebola epidemic and of Human African Trypanosomiasis (HAT) control activities between October 2013 and April 2016.</p

Canonical pathway of differentially regulated genes after LPS stimulation mediated by the NF-<i>kappa</i>B pathway.

<p>Graphical representation of the metabolic pathway LXR/RXR activation exhibited as the main metabolic pathway by the data base according to the best EV value selection. The Toll-like receptor signalling pathway enables the production of cytokines with activation of NF-<i>kappa</i>B.</p